Trials / Completed
CompletedNCT02405260
Add Glucokinase Activator to Target A1c
A Multi-Center, Adaptive Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled (Sitagliptin), Parallel Group Study to Evaluate the Safety and Efficacy of TTP399 Following 6 Months Administration in Subjects With Type 2 Diabetes Mellitus on A Stable Dose of Metformin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- vTv Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TTP399 400 mg | once daily |
| DRUG | TTP399 800 mg | once daily |
| DRUG | Sitagliptin 100 mg | once daily |
| DRUG | Placebo | once daily |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2016-07-01
- Completion
- 2016-09-01
- First posted
- 2015-04-01
- Last updated
- 2017-02-10
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02405260. Inclusion in this directory is not an endorsement.